

This item is the archived peer-reviewed author-version of:

From skeletal to cardiovascular disease in 12 steps : the evolution of sclerostin as a major player in CKD-MBD

Reference:

Brandenburg Vincent M., d' Haese Patrick C., Deck Annika, Mekahli Djalila, Meijers Björn, Neven Ellen, Evenepoel Pieter.- From skeletal to cardiovascular disease in 12 steps : the evolution of sclerostin as a major player in CKD-MBD
Pediatric nephrology - ISSN 0931-041X - 31:2(2016), p. 195-206
Full text (Publishers DOI): <http://dx.doi.org/doi:10.1007/s00467-015-3069-7>
To cite this reference: <http://hdl.handle.net/10067/1236050151162165141>

From skeletal to cardiovascular disease in 12 steps –

About the evolution of sclerostin as major player in CKD-MBD

Vincent M. Brandenburg¹, Patrick D`Haese², Annika Deck¹,

Djalila Mekahli³, Björn Meijers⁴, Ellen Neven², Pieter Evenepoel⁴

¹ Department of Cardiology, University Hospital of the RWTH Aachen, Germany;

² Laboratory of Pathophysiology, Department of Biomedical Sciences, University of Antwerp, Wilrijk, Belgium;

³ Department of Pediatric Nephrology, University Hospitals Leuven, Belgium;

⁴ Department of Immunology and Microbiology, Laboratory of Nephrology, University Hospitals Leuven, Leuven, Belgium;

Address for correspondence:

Professor Vincent M. Brandenburg, MD
Pauwelsstraße 30
D-52057 Aachen
University Hospital RWTH Aachen
Germany
Tel.: +49 (0)241/80 36072 Fax: +49 (0)241/80 82446
Vincent.Brandenburg@post.rwth-aachen.de

Abstract

Canonical Wnt signalling activity contributes to physiological and adaptive bone mineralisation and is an essential player in bone remodelling. Sclerostin is a prototypic soluble canonical Wnt signalling pathway inhibitor, which is produced in osteocytes and blocks osteoblast differentiation and function. Therefore, sclerostin is a potent inhibitor of bone formation and mineralisation. Accordingly, rodent sclerostin deficiency models exhibit a strong bone phenotype. Moreover, blocking sclerostin represents a promising treatment perspective against osteoporosis. Beyond the bone field novel data definitely show that Wnt signalling in general and sclerostin in particular are associated with ectopic extrasseous mineralisation processes, as evident in cardiovascular calcification or calciphylaxis. Uremia is characterized by the parallel occurrence of disordered bone mineralisation and accelerated cardiovascular calcification (chronic kidney disease – bone and mineral disorder, CKD-MBD), linking skeletal and cardiovascular disease – the so-called bone-vascular calcification paradox. In consequence, sclerostin may qualify as an emerging player in CKD-MBD. We present a stepwise review approach regarding the rapidly evolving field of how sclerostin participates in CKD-MBD. Starting from data originating in the classical bone field we will look separately at the three major areas of CKD-MBD, i.e. disturbed mineral metabolism, renal osteodystrophy, and uremic cardiovascular disease. Our review is intended to help the nephrologist revise the potential importance of sclerostin in CKD, by focusing on how sclerostin research is gradually evolving from the classical osteoporosis niche into the area of CKD-MBD. We will particularly integrate the limited amount of available data in the context of pediatric nephrology.

STEP 1: What is Wnt signalling?

The wingless-type mouse mammary tumor virus integration site (Wnt) pathway plays a key role in a wide array of biological processes such as cell proliferation, migration, and differentiation [1]. Wnt signalling encompasses at least three different complex pathways with partial functional overlap, one of which is the canonical Wnt/beta-catenin pathway [1, 2]. The canonical Wnt pathway involves interaction of several Wnt ligands with their cognate receptors and co-receptors [Figure 1a and Figure 1b]. Important substructures of this dual-receptor complex are formed by transmembrane Frizzled (Frz) receptors and the low-density lipoprotein receptor-related proteins (LRP) 5 and 6. The key function of the canonical Wnt

pathway is stabilization of beta-catenin by inhibiting the activity of the beta-catenin degradation complex [Figure 1a]. Beta-catenin can be considered as a central regulatory player within the cytoplasm. The function of the beta-catenin degradation complex is to phosphorylate beta-catenin through e.g. the glycogen synthase kinase (GSK)-3beta-mediated phosphorylation [Figure 1a] [3]. Phosphorylated beta-catenin is prone to proteolysis and would not accumulate in the nucleus. Only unphosphorylated beta-catenin can translocate into the nucleus and modulate target gene transcription [Figure 1b], [3].

The signalling pathways of Wnt ligands vary with the cell type involved and with the receptors and co-receptors expressed on particular effector cells. Loss-of-function mutations in key players of the canonical Wnt signalling cause distinct phenotypes as reviewed elsewhere [4]. These genetic modification models reveal the plethora of biological functions Wnt signalling is participating in. As an example individuals with LRP6 mutations exhibit premature coronary artery disease as well as severe osteoporosis [5] providing first evidence that Wnt signalling is a player in the bone-vascular axis.

Wnt signalling appears prototypic for the crosstalk within the bone-vascular axis since it encompasses vascular development and endothelial cell specification as well as the regulation of bone modelling and remodelling [6-9]. The term bone-vascular calcification paradox describes various disease states with dysregulated calcification processes characterized by the coincidence of skeletal demineralisation and vascular calcification. This calcification paradox is one of the characteristic features of CKD-MBD or vice versa, CKD-MBD is a prototypic condition for paradoxical calcification [10]. Therefore, it deserves comprehensive analyses to what extent disturbances in Wnt signalling contribute and associate with CKD.

STEP 2: What are Wnt inhibitors?

Secreted Wnt inhibitors are a group of various proteins which interfere with the extracellular binding of Wnt ligands with the transmembrane receptor complex. These inhibitors either directly bind and block Wnt ligands and thereby prevent their interactions with receptors (e.g. secreted frizzled related protein and Wnt inhibitory factor) or bind to LRP5/6, inducing receptor internalization and/or reducing their availability to Wnt ligands (e.g. Dickkopf factors [DKK] and sclerostin [Figure 1b]) [11]. Among the numerous Wnt inhibitors, DKK-1 and sclerostin have been most intensively studied – mainly in animal models and various

adult populations [9]. Directly compared with DKK-1 particularly sclerostin gained attention in the context of the bone-vascular calcification paradox. Sclerostin is a member of the cystatin-knot family of proteins and is a product of the SOST gene [12]. This glycoprotein (22 kDa) is secreted almost exclusively by osteocytes (Figure 2) and to a lesser extent by other cell types including osteoclast precursors, renal and vascular cells [13]. The major sclerostin producers – the osteocytes - are terminally differentiated osteoblasts trapped within the bone matrix. The discovery of sclerostin production contributes to our understanding that osteoblasts and osteocytes are endocrine cells secreting a number of fascinating proteins, e.g. osteoprotegerin (OPG), osteocalcin, sclerostin, and fibroblast growth factor 23 (FGF-23) [14]. Those factors and their partly quite distant physiological effects (e.g. in energy metabolism or tubular function) establish the skeleton as one of the endocrine organs [9].

STEP 3: What is the biological effect of these canonical Wnt inhibitors – particularly in bone?

The biological effects of Wnt inhibitors were first elucidated in bone. Secreted (extracellular) Wnt inhibitors such as sclerostin or DKK-1 are important negative feed-back regulators of Wnt-beta catenin signalling. Sclerostin activities are complex and besides interaction with the LRP5/6 co-receptors. There are other modes of action of sclerostin on bone metabolism, e.g. interaction with bone morphogenetic proteins [15, 16]. Additionally, sclerostin binds to LRP4, promoting receptor-blocking activities at the Frz-LRP5/6 complex [17]. Sclerostin interferes with another well-known bone metabolism regulating system: The OPG-RANK-RANKL system: Wnt signalling stimulates OPG which, in turn, binds and inhibits the receptor activator of nuclear factor kB-ligand (RANKL) expressed by osteoblasts thus preventing osteoclast precursor differentiation [18].

Wnt inhibitors allow the catenin degradation complex, consisting of APC, Axin and GSK3 [19], to degrade cytosolic beta-catenin [Figure 1b]. By doing so, Wnt inhibitors prevent beta-catenin nuclear signalling and target gene expression. Insight in the role of the various receptors, messengers and modulators of the Wnt signalling in skeletal health and disease has been gained from rodent and human genetic modification models including sclerosteosis and Van Buchem's disease [11, 20-24]. Particularly, genetic modification of sclerostin or DKK-1 activity provides comprehensive insight on how soluble Wnt inhibitors affect bone

metabolism. While reduced activity of sclerostin and DKK-1 *in vivo* contributes to increased bone mass and strength via a stimulated osteo-anabolic action [23, 25], the opposite is true in experimental models with overexpression of both sclerostin or DKK-1 [12, 26]. These models reveal how potent the anti-anabolic actions of sclerostin and DKK-1 are. Moreover, transgenic overexpression of sclerostin was associated with chondrodysplasia in lumbar vertebrae. The vertebrae were also shorter, wider and lacked the normal trabecular and inter-vertebral disc architecture [12]. Interestingly, the observed high bone formation and mineralization indices typically detected in sclerostin-null mice might, at least in part, be related to significantly increased 1,25 dihydroxyvitamin D levels and significantly reduced FGF-23 levels in these animals compared to wild type mice [27]. With all these data in mind it is surprising to see a positive association between serum sclerostin levels and high bone mineral density in humans which at first sight is counter-intuitive [28]. Register and co-workers speculated that high levels of circulating sclerostin might be indicative of impaired receptor binding and therefore reduced local skeletal activity [28]. However, this assumption as well as the potential role of PTH resistance herein needs further investigation and especially confirmation in patients with CKD. Sclerostin levels are modified and influenced – among others - by age, fracture healing, gender, estrogen usage, hyperparathyroidism, and physical activity. Although beyond the scope of the present review it is justified to summarize that the absence or presence of such (patho)physiological stimuli or suppressors of bone metabolism influences sclerostin [29-31]. It is needless to say that any conclusion of analogy between bone physiology in non-renal patients and the state CKD-MBD regarding such interactions should be drawn with substantial caution.

In summary the osteocyte and its SOST gene product sclerostin are outstanding regulators of bone metabolism and target structures for several extraskeletal mediators. Viable osteocytes regulate the proper functionality of the skeleton which – as outlined below- has in turn substantial effects beyond bone metabolism [9, 32, 33].

STEP 4: Is targeting canonical Wnt signalling clinically meaningful?

Targeting Wnt signalling offers fascinating clinical perspectives – currently expected to be most beneficial in the bone field [11]. To date, interfering with Wnt signalling by blocking sclerostin has advanced the most in postmenopausal osteoporotic patients. In a recent 12 months phase-2 trial, blocking sclerostin activity by monoclonal antibodies increases

significantly bone mass in postmenopausal osteoporosis [34]. The trial compared the efficacy of various anti-osteoporotic therapies (alendronate, teriparatide) with different dosages of romosozumab, a human monoclonal sclerostin-antibody, through evaluation of lumbar and femoral bone mineral density in 419 women with low bone mass. Bone mass was assessed by densitometry at the lumbar spine and the femoral neck. Additionally, the authors investigated the development of serum levels of markers of bone metabolism over time. The primary end point was the percentage change from baseline in bone mineral density at the lumbar spine. Compared to placebo, as well as to the two other active intervention arms (teriparatide and alendronate), romosozumab treated patients exhibited a significant, dose-dependent bone mineral density increase up to 11.3% at the lumbar spine, 4.1% at the total hip, and 3.7% at the femoral neck. In parallel, the study revealed a (transient) increase in bone formation markers and a decrease in bone resorption markers. The authors of this trial speculate about the assumed safety of romosozumab treatment with two major arguments: *First*, heterozygous human carriers of SOST mutations have a benign clinical course with high bone density but without clinical signs of bone overgrowth such as nerve compression symptoms [35]; *second*, the authors claim that SOST expression is limited to the skeleton and therefore blocking sclerostin activity is limited to the skeleton, too. However, this might actually be an over-simplification and step 9 of the present review will describe concerns about unpredictable extra-skeletal effects of romosozumab which recently have been announced by our group [36].

Step 5: Why is sclerostin in particular the most promising parameter to consider among the various Wnt-inhibitors in the concert of CKD-MBD?

Both sclerostin and DKK-1 are prototypic soluble Wnt inhibitors [11]. The - still limited - data that is currently available regarding the potential association and diagnostic value in terms of relevant CKD-MBD parameters is insufficient to attribute clear "scientific" or "clinical" superiority to either sclerostin or DKK-1. However, several lines of evidence support our view that sclerostin is one step ahead of DKK-1 in bone and also vascular research. This evidence is fuelled e.g. by the numbers of publications (e.g. retrieved via Pubmed search for "DKK-1" versus "sclerostin" as updated in September 2014). Sclerostin research is also more advanced in terms of treatment for human osteoporosis as already pointed out in step 4. A large-scale phase III trial is on the way to compare the efficacy of fracture prevention

between romosozumab and alendronate in osteoporotic postmenopausal women (ClinicalTrials.gov Identifier: NCT01631214). It is important to note that DKK-1 and sclerostin exhibit distinct biological effects and are differently regulated [17, 37, 38]. In this context it has been hypothesized that sclerostin exerts more specific regulatory actions within the Wnt cascade, while DKK-1 is more a pan-Wnt inhibitor encompassing different Wnt pathways [11]. Accordingly, notable differences exist between the two rodent knock-out models *SOST*^{-/-} and *DKK-1*^{-/-}. While *SOST*^{-/-} mice present a macroscopically rather unremarkable phenotype with the predominant characteristic finding of strong bones, DKK-1 null mutant embryo's lack head structures anterior of the midbrain [39] which is associated with premature death. These animal models suggest that sclerostin activity appears to be more focused upon (although not limited to) mineralization processes. Therefore, therapeutic interventions targeting sclerostin might produce more predictable effects as compared to DKK-1. Also, the association between sclerostin and DKK-1 serum levels and cardiovascular calcification are opposite [40]. Thus, the available evidence suggests that it is not justified to simply lump these two inhibitors together. Instead, sclerostin and DKK-1 should be considered two different types of Wnt-inhibitors, despite some homologies and similarities. Based on the amount and quality of data available the following sections focus mainly on sclerostin.

Step 6: Potential role of Wnt inhibitors in nephrology

The Wnt signalling pathway plays an important role in renal (patho)physiology via its involvement in nephrogenesis [41], renal repair, and fibrosis [42]. Experimental renal failure dramatically upregulates renal beta-catenin production [42]. This goes along with an increased expression of DKK-1 and sclerostin, as recently observed in the tubular epithelium of mice subjected to renal injury mimicking stage 2 CKD [43]. In addition, "standard" nephrological therapeutics such as vitamin D [42] and ACE-inhibition [44] interfere with the Wnt signalling cascade.

Given the important role of Wnt signalling in the biology of bone and vasculature it is tempting to speculate about the potential role of Wnt-signalling in CKD-MBD. In particular, what is the contribution of sclerostin and DKK-1 to CKD-MBD [45]? CKD-MBD encompasses three major disturbances associated with reduced renal function: bone disease, cardiovascular disorders, and dysregulated mineral metabolism [10]. Especially sclerostin fulfils the prerequisites to qualify as relevant new player (biomarker) in CKD-MBD. These are: (i) CKD

on itself influences the candidate biomarker in terms of concentration and / or biological activity and (ii) there are links between the candidate biomarker and all three aspects of CKD-MBD. Indeed, CKD in humans associates with signs of disturbed Wnt signalling. Compared to adult individuals with normal renal function, circulating levels of both DKK-1 and sclerostin are increased in humans with advanced or end-stage renal disease (ESRD) [46]. Sclerostin levels gradually increase from healthy individuals over patients with calcifying arteriosclerosis to heavily calcified dialysis patients [46]. It has not yet been fully determined to what extent this reflects increased production, renal retention or both. As far as sclerostin is concerned, recent clinical data argue against simple renal retention, since in parallel with increasing serum concentrations also urinary sclerostin concentrations as well as fractional sclerostin excretion increased with declining renal function (the latter from $0.45\pm0.26\%$ in patients with CKD stage 1 to $26\pm18\%$ ($n=15$) in CKD stage 5 ($n=19$) [47]. Serum levels rapidly return to the normal range following successful renal transplantation [48]. In case elevated sclerostin levels are not solely consequential to renal retention, increased production comes into play. The bone compartment is one candidate for increased production. However, the exact source of sclerostin detected in the circulation is not yet known. *In vivo* evidence has been provided that osseous sclerostin expression is upregulated in early CKD as detected by analyzing mouse models of moderate renal failure (juvenile cystic kidney (jck) mouse, a genetic model for polycystic kidney disease) [49]. The jck mouse is characterized by biochemical changes (starting at about week 10), cardiovascular abnormalities (starting at about week 15), and skeletal changes (starting at about week 9) typically seen in CKD-MBD [49]. As previously speculated, sclerostin production at sites outside the skeleton – e.g. the calcified vasculature might also occur in CKD-MBD and contribute via “spill-over” to the observed serum levels [46, 47, 50]. In case sclerostin metabolism is altered in CKD (i.e. the above-mentioned requirement (i) is fulfilled) - what about the second item (ii) – is there a causal association with the CKD-MBD or is sclerostin entirely innocent?

STEP 7: Sclerostin associates with various CKD-MBD-related biomarkers

In contrast to the highly elevated PTH levels (up to factor 20, 30 or even more) and in particularly FGF-23 levels (up to factor 1000 above the upper normal limit) in patients with ESRD, circulating sclerostin concentrations are only moderately, however significantly, increased by a factor 2 to 3 [46]. These ESRD-related sclerostin levels reveal significant

associations with the classical CKD-MBD biomarkers such as PTH. Plasma sclerostin levels within the NECOSAD cohort (NEtherlands COoperative Study on the Adequacy of Dialysis) cohort ($n=673$, age 63 ± 14 yrs, mean serum sclerostin (ELISA) 1.24 ± 0.57 ng/mL) were negatively correlated with PTH levels ($r = -0.25$, $p<0.001$) [51].

Other researchers confirmed statistically relevant associations between sclerostin and classical CKD-MBD parameters in serum of CKD patients (e.g. with FGF-23 [52]). These mathematical correlations may reflect a biological (causal) background as described below for the interaction between sclerostin and PTH (PTH suppresses sclerostin expression in osteocytes). Sclerostin is thought to participate in several biochemical feed-back loops, as evidenced by the fact that sclerostin-deficient mice reveal alterations in a number of classical biochemical CKD-MBD-related parameters [27]. While serum calcium and PTH levels were not different between sclerostin-knockout and wild type-mice, FGF-23 levels were about 2.5 times lower in sclerostin-deficient mice compared to their wild types and vice versa 1,25-dihydroxyvitamin D and serum phosphate levels were significantly elevated. Sclerostin alters vitamin D synthesis in proximal tubular cells [27]. Hence, the above-mentioned endocrine skeletal activity of sclerostin is not limited to paracrine effects. Taken together, elevated concentrations of circulating sclerostin (plasma, serum) are a novel player participating in the biochemical concert of CKD-MBD alterations.

Step 8: Wnt signalling and inhibitors in uremic bone disease

An important aspect to consider is a potentially causal role of Wnt signalling and its dysregulation, respectively, in the development of renal osteodystrophy. Data regarding how sclerostin and DKK-1 can cause or mediate renal osteodystrophy are still sparse. The absence of sclerostin in rodent models undoubtedly is associated with a high bone mass and a “healthy” bone phenotype as reviewed above. So theoretically, uremic SOST overexpression might be one contributor to disturbed bone metabolism as seen in renal osteodystrophy (low bone mass and altered metabolism).

PTH downregulates sclerostin expression in osteocytes and this interaction represents an important aspect of how PTH stimulates bone metabolism [53]. There is substantial experimental evidence available that a balanced cross-talk between PTH and sclerostin is relevant for bone physiology. PTH administration rapidly reduces sclerostin mRNA as well as protein production in osteocytes [53, 54]. In healthy conditions, PTH anabolism to a certain

extent is mediated by suppressing the anti-anabolic activity of sclerostin. Patients with primary hyperparathyroidism have lower serum sclerostin. As already discussed, a negative correlation has been reported between PTH and sclerostin concentrations both in renal and non-renal individuals [51, 55]. Kramer and co-workers convincingly showed how much skeletal PTH actions rely upon sclerostin physiology [25]. They investigated the effects of intermittent PTH-administration in mouse models with sclerostin overexpression and also with sclerostin deficiency. Six-months old genetically engineered mice underwent a two-months treatment period with 1-34 PTH. Both sclerostin-deficient as well as sclerostin overexpressing mice revealed the expected skeletal phenotype, i.e. high bone mass in the former and severe osteopenia in the latter. In both these genetically engineered mouse models the response to intermittent PTH treatment in terms of stimulation of bone metabolism was significantly diminished. Therefore the authors came to the conclusion that suppressibility of sclerostin in osteocytes is necessary to mediate anabolic responses to PTH [25]. Another interesting aspect within this context is that PTH exerts its bone anabolic effects also via LRP6 – as already discussed an important co-receptor within the canonical Wnt signalling [56].

Conditions associated with supra-physiological sclerostin activity thus may impede PTH-mediated bone anabolism. Adynamic bone disease (ABD) is a subtype of renal osteodystrophy characterized by substantially reduced bone formation rate, impaired remodelling activity and reduced osteoblastic and osteoclastic activity [57] (**Figure 3**). In uremia, high sclerostin levels may exacerbate PTH-resistance, which could cause and /or aggravate ABD. Bone biopsy findings support this theory. A study in which 60 adult dialysis patients underwent a bone biopsy after tetracycline labelling revealed a statistically negative correlation between serum sclerostin and PTH [58]. Most importantly, sclerostin showed strong negative associations with parameters of bone turnover pointing towards a role of high sclerostin levels in the development of ABD [58]. So the slightly elevated PTH levels in ABD might actually resemble a state of relative hypoparathyroidism in which PTH cannot overcome skeletal actions of bone suppressive mediators contributing to uremic PTH resistance of bone. Based on our current knowledge sclerostin qualifies as a suitable candidate to aggravate this PTH resistance. Experimental evidence indicates that the phosphorus load triggers development of renal osteodystrophy and that this causative role may at least in part be mediated via stimulation of sclerostin expression [59]. Ferreira and

co-workers performed subtotal nephrectomy and total parathyroidectomy in rats, which afterwards were fed a high or low-phosphorus diet for 8 weeks. Compared to the 0.6% phosphorus diet, the 1.2% phosphorus diet significantly stimulated SOST gene expression in tibial tissue and serum sclerostin levels (about 8 times higher each). This in turn was associated with a lower bone volume. However, bone formation rate per bone surface as sensitive marker for ABD was comparable between the two diets [59].

A very recent publication about the *jck* mouse model, *i.e. a mouse model of moderate renal failure*, contributed remarkably to our understanding about the timely evolution of CKD-MBD parameters during the course of the disease [49]. Interestingly, osteocytic sclerostin expression and consecutive suppression of beta-catenin signalling in this mouse model occurs earlier (week 5) than biochemical changes in serum PTH or FGF-23 (week 10). The increased sclerostin expression also preceded cardiovascular (starting at about week 15), and skeletal (starting at about week 9) changes typically seen in CKD-MBD (34). The rise in sclerostin-positive osteocytes was transient and diminished with increasing hyperparathyroidism. These findings turn sclerostin alterations to a particularly interesting CKD-MBD parameter, since the time course of activation might point towards causality.

STEP 9: Wnt signalling and inhibitors in (uremic) vascular disease

Wnt signalling plays a role in human atherosclerosis [60] and missense mutations in LRP6 are associated with premature coronary artery disease and osteoporosis [5]. Another study showed that rare (611C) and common (1062V) loss-of-function variants of LRP6 display reduced activation of Wnt/beta-catenin signalling. The rare gene variant 611C was associated with hypertension, metabolic abnormalities, and early coronary artery disease. Moreover, also the more common variant 1062V of LRP6 associates strongly with the presence of coronary artery disease in hypertensive patients [61].

Vitamin K antagonist treatment such as warfarin is suspected to trigger vascular calcification [62, 63]. Beazley and co-workers showed that warfarin activates beta-catenin signalling in VSMCs *in vitro* by (i) increasing the amount of total beta-catenin protein, by (ii) upregulating its nuclear translocation and by (iii) stimulating transcription of beta-catenin target genes [64]. To the best of our knowledge there are no data regarding the cardiovascular status in sclerostosis, van Buchem's disease or mice with genetically modified sclerostin expression. While participation of Wnt signalling in general atherosclerosis has already been extensively

reviewed [60], the particular role of sclerostin - and also DKK-1 - in uremic vascular disease is a novel, evolving field. Their role is currently incompletely understood, since previous findings are partly contradictory and important research questions have not been addressed yet. Recent research indicates that in human aortic valve tissue from hemodialysis patients with microscopic as well as macroscopic calcification a significant local sclerostin mRNA upregulation is detectable which is absent in aortic valve tissue from hemodialysis patients without calcification [46]. So it is not uremia *per se* but the calcification process which is seemingly responsible for local sclerostin expression in the vascular system. Similarly local sclerostin deposition was detectable in human atherosclerotic lesions via IHC staining [Figure 4, courtesy of Dr. Nadine Kaeleser, Aachen]. This up-regulated local expression in calcified tissue is accompanied by augmented circulating levels of sclerostin which gradually increase - when measured with the same ELISA - from non-uremic individuals without calcific aortic disease to patients with either one of the diseases towards uremic patients plus in parallel calcific aortic disease [46]. It remains unclear whether elevated serum sclerostin levels originate from the vasculature or the bone or both [46, 49]. Experimental *in vitro* data from Zhu and co-workers confirm sclerostin expression in calcifying vascular smooth muscle cells (VSMCs) [65]. *In vitro*, VSMCs express osteocytic markers when grown in a pro-calcific environment indicative of an osteoblastic to osteocytic transition (terminal transdifferentiation) [65]. Accordingly, the same authors found *in vivo* expression of sclerostin in calcified mouse aortas. Occurrence of sclerostin in calcified aortic valve tissue is not limited to hemodialysis patients but also in patients with dominant calcific aortic stenosis [66]. Moreover, ectopic sclerostin production and deposition was also detectable in skin specimen from patients with calciphylaxis [Figure 5] [67], while no such local sclerostin was found in control skin specimen from dialysis patients without cutaneous calcification. Vascular calcification can be quantified by non-invasive means such as X-ray or computed tomography and several reports about the association between calcification burden and serum sclerostin levels have been published: The correlation between calcification and circulating sclerostin was described as positive in non-uremic calcific aortic stenosis [66], in uremia-associated calcific aortic stenosis [46] and in aortic artery calcification in postmenopausal women [40]. However, no such statistically significant correlation has been reported between uremia-associated coronary artery calcification and sclerostin levels [46]. Of note, even contradictory findings were published: Register and coworkers [28]

investigated vascular calcification in 450 diabetic African-Americans. After fully adjustments only calcification of the carotid artery in men (not women) remained inversely and significantly associated with serum sclerostin [28]. Similarly, Claes et al also found that lower, not higher, sclerostin levels were determined as independent predictors of aortic calcification as assessed by lumbar X-ray in a cohort of 154 CKD patients [68]. Interpretation of these heterogeneous and partly conflicting data needs to take into account the anatomical structures (aortic valve, coronary artery, large elastic arteries), heterogeneity of study populations (particularly dialysis versus non-dialysis cohorts), different calcification detection methods as well as technical differences between various sclerostin assays. It is important to mention that comparisons of mean Wnt inhibitor levels between cohorts should be limited to samples analyzed with the same assays [46, 66]. Our group e.g. previously used to different ELISA-based sclerostin assays in hemodialysis patients (Biomedica, Austria and TECOMedical, Switzerland). Using the TECOMedical assay in 673 patients the mean serum level was determined as 1.24 ± 0.57 ng/mL [51], which is different to the median level of 110 (82-151) pmol/L obtained in 100 hemodialysis patients [50]. Moreover, gender- and diabetes-related differences regarding sclerostin levels could only be obtained within the latter cohort and the Biomedica assay [50]. We are currently unable to define diagnostic superiority of one of these two assays, but such studies are on their way.

Taken together, Wnt signalling activity in general and sclerostin activity in particular are linked to ectopic, vascular calcification processes and therefore exert calcification effects beyond bone mineralisation. Further research needs to determine whether sclerostin's role in arteriosclerosis is pro- or anti-calcific and whether this role might vary dependent on background conditions, e.g. CKD.

STEP 10: Determination of Wnt signalling and outcome – is there a link?

Since vascular calcification influences cardiovascular event rate and mortality in CKD patients, researchers also explored the relationship between sclerostin and future outcome in ESRD patients. This association was e.g. assessed in the NECOSAD cohort [51]. After adjustment for various clinical and biochemical parameters, patients in the highest sclerostin tertile three months after initiation of dialysis had a significantly lower risk of cardiovascular death (HR 0.29, 95% CI 0.13-0.62) and for all-cause mortality (0.39, 95% CI 0.22-0.68) within 18 months compared to patients of the lowest tertile. These findings are not in line with a

previously published smaller cohort in CKD patients, in which the authors detected a reciprocal sclerostin effect upon mortality; i.e. levels above the median were associated with worse cardiovascular outcome [52]. Another study by Viaene and co-workers dichotomised a cohort of long-term dialysis patients according to the median level of sclerostin and detected a significant survival benefit for patients above the median after adjusting for age and gender (HR 0.33, 95%CI 0.15 – 0.73, p=0.006). However, within a fully adjusted model including bone-specific alkaline phosphates the association between survival and sclerostin lost statistical significance [50]. Again, data are not homogeneous. Similarly to the situation in the above-mentioned calcification studies, also these three survival studies were made in cohorts with different clinical background and they applied different sclerostin assays – factors that potentially influence these findings. It remains an open question whether sclerostin will ever qualify as biomarker for cardiovascular health status and for survival prediction in CKD-MBD.

Step 11: Sclerostin in pediatric populations

To our knowledge, no data are available on sclerostin in CKD or ESRD children and adolescents. The role of sclerostin in the growing skeleton under uremic conditions has not yet been investigated. Since puberty is the time when 25-50% of the adult bone mass is accrued, the growing skeleton might be particularly vulnerable to over-activity of Wnt-signalling inhibitors. Very few data are recently published on sclerostin in pediatric populations and these are conflicting. On the one hand it has been demonstrated that sclerostin levels increase with age in adults of both sexes with a significantly higher levels in men comparing to women [69]; on the other hand Fischer et al. showed in a cross-sectional study of 424 healthy children, adolescents and young adults (aged 0.1-21 years, 221 males) that sclerostin levels were independent of age and gender [70]. However, Kirmani et al. showed that sclerostin levels were higher in boys than in girls and this gender difference appears already during puberty, pointing towards a role of estrogen in reducing the sclerostin levels [71] Furthermore, they demonstrated that serum sclerostin levels peak early in life (at about age 10 years in girls and 14 years in boys), decline during the later stages of puberty towards a nadir at the end of puberty, and then increase again over the remaining adult lifetime.

Step 12: The future: research perspectives regarding sclerostin in CKD-MBD

We consider the following open questions as important issues and we think they qualify as research targets in order to better define the role of sclerostin in CKD-MBD:

- 1) Assay reliability and comparability for sclerostin measurements needs to be assessed prior to implementation of sclerostin measurement in clinical practice.
- 2) It is unknown whether and to what extend nephrological standard of care, e.g. active vitamin D or calcimimetics, alters levels of soluble Wnt inhibitors.
- 3) The potential association between sclerostin serum levels and outcome should translate into research efforts defining whether therapeutical modification of sclerostin levels associates with modified outcome.
- 4) It is not known to what extent circulating Wnt signalling inhibitor levels in CKD patients originate from the vasculature or the bone. At least in postmenopausal women, serum sclerostin levels correlate closely with bone marrow plasma levels, suggesting that serum levels, at least to some extent, reflect status in the bone microenvironment [72]. So further research needs to define the origin of increased blood levels of sclerostin and if circulating levels in CKD-MBD patients reflect distinct tissue activities.
- 5) Further research is needed to explore to what extent increased local and or systemic Wnt signalling antagonistic activities contribute to renal osteodystrophy in general and particularly to adynamic bone disease.
- 6) The potential impact of disturbed Wnt signalling in children and adolescents with CKD or ESRD deserves special attention. We need to evaluate how Wnt signalling participates in the regulation of bone mass and structure during this critical period for skeletal development under uremic conditions.
- 7) The potential contribution of Wnt signalling in uremic vascular disease as reflected e.g. by local tissue activities of sclerostin fuels speculations about a contribution of Wnt signalling in accelerated uremic arteriosclerosis. More research is needed to clarify the role of sclerostin as pro- or anti-calcific.
- 8) While anti-sclerostin antibodies theoretically may help to overcome situations with over-suppressed bone metabolism in uremia (=adynamic bone disease) it seems of outstanding importance to further investigate the consequences of therapeutic blockade of sclerostin in accelerated uremic calcification.

Summary and conclusion

In summary, sclerostin made its way down the road from the bone niche to the cardiovascular field. Due to its strong links to CKD sclerostin qualifies as a novel mediator of CKD-MBD. Based on our current knowledge sclerostin may be considered as one of the driving forces of the calcification paradox in the bone-vascular axis. The available data about sclerostin and CKD-MBD as summarized in the present review originate solely from studies in adults. Corresponding data from children are absent, yet it is tempting to speculate how sclerostin might be involved in adolescent CKD-MBD. These gaps in our understanding bring us directly to potential future research targets and make us speculate about what burning questions should be urgently addressed.

Figure legends

Figure 1a: Soluble Wnt ligands bind to a receptor complex consisting of Frizzled and LDL-receptor-related protein 5 and 6 (LRP5/6). Upon extracellular Wnt ligand binding the receptor complex interacts with the phosphoprotein Dishevelled (Dsh), which is located in the cytoplasm. Wnt ligand binding and activation of Dsh result in the relocation of Axin to the plasma membrane receptor complex resulting in disassembly of the β -catenin degradation complex. This destruction complex consists of casein kinase 1 (CK1), Axin, adenomatous polyposis coli (APC), and glycogen synthase kinase 3 (GSK 3) (the multimeric CK1-APC-GSK3-Axin complex). β -catenin is consecutively released from this complex and stabilized since the absence of phosphorylation prevents degradation. In consequence, unphosphorylated β -catenin accumulates, translocates into the nucleus and modifies gene transcription via its role as coactivator of transcription factors that belong to the TCF/LEF family.

Figure 1b: In the presence of the soluble Wnt inhibitor sclerostin Wnt ligands are blocked from binding the LRP5/6-Frizzled receptor complex which allows in turn activation the β -catenin degradation complex (CK-APC-GSK3-Axin complex). Phosphorylation of β -catenin by GSK3 and CK1 blocks the translocation of β -catenin into the nucleus and enhances β -catenin degradation via proteolysis.

Figure 2: Immunohistochemical staining of sclerostin indicating the expression of the protein by osteocytes (arrows); BM = bone marrow; MB = mineralized bone

Figure 3: Goldner stained section of adynamic bone. Absence of active osteoblasts, osteoclasts and osteoid point to the presence of adynamic bone.

Figure 4: Example of immunohistochemical staining for sclerostin in human atherosclerotic lesions of a resected internal carotid artery (arrows) (courtesy of Dr. Nadine Kaesler, Aachen).

Figure 5: Immunohistochemical staining for sclerostin of a skin specimen from a dialysis patient with calciphylaxis (arrows). Specimen was obtained in close proximity to an ulcerative lesion of dialysis-associated calciphylaxis (bar 200 μ m)

Reference List

1. Kestler HA, Kuhl M (2008) From individual Wnt pathways towards a Wnt signalling network. *Philos Trans R Soc Lond B Biol Sci* 363:1333-1347
2. Kim W, Kim M, Jho EH (2013) Wnt/beta-catenin signalling: from plasma membrane to nucleus. *Biochem J* 450:9-21
3. Monroe DG, McGee-Lawrence ME, Oursler MJ, Westendorf JJ (2012) Update on Wnt signaling in bone cell biology and bone disease. *Gene* 492:1-18
4. Kubota T, Michigami T, Ozono K (2010) Wnt signaling in bone. *Clin Pediatr Endocrinol* 19:49-56
5. Mani A, Radhakrishnan J, Wang H, Mani A, Mani MA, Nelson-Williams C, Carew KS, Mane S, Najmabadi H, Wu D, Lifton RP (2007) LRP6 mutation in a family with early coronary disease and metabolic risk factors. *Science* 315:1278-1282
6. Dejana E (2010) The role of wnt signaling in physiological and pathological angiogenesis. *Circ Res* 107:943-952
7. Johnson ML, Kamel MA (2007) The Wnt signaling pathway and bone metabolism. *Curr Opin Rheumatol* 19:376-382
8. Rajamannan NM (2011) The role of Lrp5/6 in cardiac valve disease: LDL-density-pressure theory. *J Cell Biochem* 112:2222-2229
9. Vervloet MG, Massy ZA, Brandenburg VM, Mazzaferro S, Cozzolino M, Urena-Torres P, Bover J, Goldsmith D (2014) Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. *Lancet Diabetes Endocrinol* 2:427-436
10. Cozzolino M, Urena-Torres P, Vervloet MG, Brandenburg V, Bover J, Goldsmith D, Larsson TE, Massy ZA, Mazzaferro S (2014) Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome? *Nephrol Dial Transplant* 29:1815-1820
11. Ke HZ, Richards WG, Li X, Ominsky MS (2012) Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. *Endocr Rev* 33:747-783
12. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. *EMBO J* 22:6267-6276
13. Poole KE, van Bezooyen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, Reeve J (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. *FASEB J* 19:1842-1844
14. Capulli M, Paone R, Rucci N (2014) Osteoblast and osteocyte: Games without frontiers. *Arch Biochem Biophys* 561:3-12
15. Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ (2008) Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. *Proc Natl Acad Sci U S A* 105:20764-20769
16. Baron R, Rawadi G (2007) Wnt signaling and the regulation of bone mass. *Curr Osteoporos Rep* 5:73-80
17. Choi HY, Dieckmann M, Herz J, Niemeier A (2009) Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. *PLoS One* 4:e7930
18. Glass DA, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G (2005) Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. *Dev Cell* 8:751-764
19. Schmitz Y, Rateitschak K, Wolkenhauer O (2013) Analysing the impact of nucleo-cytoplasmic shuttling of beta-catenin and its antagonists APC, Axin and GSK3 on Wnt/beta-catenin signalling. *Cell Signal* 25:2210-2221
20. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP (2002) High bone density due to a mutation in LDL-receptor-related protein 5. *N Engl J Med* 346:1513-1521
21. Babij P, Zhao W, Small C, Kharode Y, Yaworsky PJ, Bouxsein ML, Reddy PS, Bodine PV, Robinson JA, Bhat B, Marzolf J, Moran RA, Bex F (2003) High bone mass in mice expressing a mutant LRP5 gene. *J Bone Miner Res* 18:960-974
22. Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, Dioszegi M, Dikkers FG, Hildering P, Willems PJ, Verheij JB, Lindpaintner K, Vickery B, Foernzler D, Van Hul W (2002) Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. *J Med Genet* 39:91-97

23. Morvan F, Boulukos K, Clement-Lacroix P, Roman RS, Suc-Royer I, Vayssiere B, Ammann P, Martin P, Pinho S, Pognonec P, Mollat P, Niehrs C, Baron R, Rawadi G (2006) Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. *J Bone Miner Res* 21:934-945
24. Robinson MK, Caminis J, Brunkow ME (2013) Sclerostin: how human mutations have helped reveal a new target for the treatment of osteoporosis. *Drug Discov Today* 18:637-643
25. Kramer I, Loots GG, Studer A, Keller H, Kneissel M (2010) Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. *J Bone Miner Res* 25:178-189
26. Yao GQ, Wu JJ, Troiano N, Insogna K (2011) Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice. *J Bone Miner Metab* 29:141-148
27. Ryan ZC, Ketha H, McNulty MS, McGee-Lawrence M, Craig TA, Grande JP, Westendorf JJ, Singh RJ, Kumar R (2013) Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. *Proc Natl Acad Sci U S A* 110:6199-6204
28. Register TC, Hruska KA, Divers J, Bowden DW, Palmer ND, Carr JJ, Wagenknecht LE, Hightower RC, Xu J, Smith SC, Dietzen DJ, Langefeld CD, Freedman BI (2014) Sclerostin is positively associated with bone mineral density in men and women and negatively associated with carotid calcified atherosclerotic plaque in men from the African American-Diabetes Heart Study. *J Clin Endocrinol Metab* 99:315-321
29. Dovjak P, Dorfer S, Foger-Samwald U, Kudlacek S, Marculescu R, Pietschmann P (2014) Serum levels of sclerostin and dickkopf-1: effects of age, gender and fracture status. *Gerontology* 60:493-501
30. Viapiana O, Fracassi E, Troplini S, Idolazzi L, Rossini M, Adami S, Gatti D (2013) Sclerostin and DKK1 in primary hyperparathyroidism. *Calcif Tissue Int* 92:324-329
31. Amrein K, Amrein S, Drexler C, Dimai HP, Dobnig H, Pfeifer K, Tomaschitz A, Pieber TR, Fahrleitner-Pammer A (2012) Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. *J Clin Endocrinol Metab* 97:148-154
32. Bonewald LF (2011) The amazing osteocyte. *J Bone Miner Res* 26:229-238
33. Baron R, Kneissel M (2013) WNT signaling in bone homeostasis and disease: from human mutations to treatments. *Nat Med* 19:179-192
34. McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG (2014) Romosozumab in postmenopausal women with low bone mineral density. *N Engl J Med* 370:412-420
35. van Lierop AH, Hamdy NA, Hamersma H, van Bezooijen RL, Power J, Loveridge N, Papapoulos SE (2011) Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. *J Bone Miner Res* 26:2804-2811
36. Evenepoel P, D'Haese P, Brandenburg V (2014) Romosozumab in postmenopausal women with osteopenia. *N Engl J Med* 370:1664
37. Nakamura T, Nakamura T, Matsumoto K (2008) The functions and possible significance of Kremen as the gatekeeper of Wnt signalling in development and pathology. *J Cell Mol Med* 12:391-408
38. Gifre L, Ruiz-Gaspa S, Monegal A, Nomdedeu B, Filella X, Guanabens N, Peris P (2013) Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. *Bone* 57:272-276
39. Mukhopadhyay M, Shtrom S, Rodriguez-Esteban C, Chen L, Tsukui T, Gomer L, Dorward DW, Glinka A, Grinberg A, Huang SP, Niehrs C, Izpisua Belmonte JC, Westphal H (2001) Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse. *Dev Cell* 1:423-434
40. Hampson G, Edwards S, Conroy S, Blake GM, Fogelman I, Frost ML (2013) The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. *Bone* 56:42-47
41. Vivante A, Mark-Danieli M, Davidovits M, Harari-Steinberg O, Omer D, Gnatek Y, Cleper R, Landau D, Kovalski Y, Weissman I, Eisenstein I, Soudack M, Wolf HR, Issler N, Lotan D, Anikster Y, Dekel B (2013) Renal hypodysplasia associates with a WNT4 variant that causes aberrant canonical WNT signaling. *J Am Soc Nephrol* 24:550-558
42. He W, Kang YS, Dai C, Liu Y (2011) Blockade of Wnt/beta-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. *J Am Soc Nephrol* 22:90-103

43. Fang Y, Ginsberg C, Seifert M, Agapova O, Sugatani T, Register TC, Freedman BI, Monier-Faugere MC, Malluche H, Hruska KA (2014) CKD-Induced Wingless/Integration1 Inhibitors and Phosphorus Cause the CKD-Mineral and Bone Disorder. *J Am Soc Nephrol* 25:1760-1773
44. Floege J (2014) Antagonism of Canonical Wnt/beta-Catenin Signaling: Taking RAS Blockade to the Next Level? *J Am Soc Nephrol* [epub ahead of print]:
45. Cannata-Andia JB, Roman-Garcia P, Hruska K (2011) The connections between vascular calcification and bone health. *Nephrol Dial Transplant* 26:3429-3436
46. Brandenburg VM, Kramann R, Koos R, Kruger T, Schurgers L, Muhlenbruch G, Hubner S, Gladziwa U, Drechsler C, Ketteler M (2013) Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. *BMC Nephrol* 14:219
47. Cejka D, Marculescu R, Kozakowski N, Plischke M, Reiter T, Gessl A, Haas M (2014) Renal elimination of sclerostin increases with declining kidney function. *J Clin Endocrinol Metab* 99:248-255
48. Bonani M, Rodriguez D, Fehr T, Mohebbi N, Brockmann J, Blum M, Graf N, Frey D, Wuthrich RP (2014) Sclerostin Blood Levels Before and After Kidney Transplantation. *Kidney Blood Press Res* 39:230-239
49. Sabbagh Y, Graciolli FG, O'Brien S, Tang W, dos Reis LM, Ryan S, Phillips L, Boulanger J, Song W, Bracken C, Liu S, Ledbetter S, Dechow P, Canziani ME, Carvalho AB, Jorgetti V, Moyses RM, Schiavi SC (2012) Repression of osteocyte Wnt/beta-catenin signaling is an early event in the progression of renal osteodystrophy. *J Bone Miner Res* 27:1757-1772
50. Viaene L, Behets GJ, Claes K, Meijers B, Blocki F, Brandenburg V, Evenepoel P, D'Haese PC (2013) Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? *Nephrol Dial Transplant* 28:3024-3030
51. Drechsler C, Evenepoel P, Vervloet MG, Wanner C, Ketteler M, Marx N, Floege J, Dekker FW, Brandenburg VM (2014) High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. *Nephrol Dial Transplant* [epub ahead of print]:
52. Kanbay M, Siriopol D, Saglam M, Gulcan KY, Gok M, Cetinkaya H, Karaman M, Umut UH, Oguz Y, Sari S, Eyileten T, Goldsmith D, Vural A, Veisa G, Covic A, Ilker YM (2014) Serum sclerostin and adverse outcomes in non-dialyzed chronic kidney disease patients. *J Clin Endocrinol Metab* 120:2042-2042
53. Bellido T, Saini V, Pajevic PD (2013) Effects of PTH on osteocyte function. *Bone* 54:250-257
54. Keller H, Kneissel M (2005) SOST is a target gene for PTH in bone. *Bone* 37:148-158
55. Durosier C, van Lierop A, Ferrari S, Chevalley T, Papapoulos S, Rizzoli R (2013) Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women. *J Clin Endocrinol Metab* 98:3873-3883
56. Li C, Xing Q, Yu B, Xie H, Wang W, Shi C, Crane JL, Cao X, Wan M (2013) Disruption of LRP6 in osteoblasts blunts the bone anabolic activity of PTH. *J Bone Miner Res* 28:2094-2108
57. Cannata-Andia JB, Rodriguez GM, Gomez AC (2013) Osteoporosis and adynamic bone in chronic kidney disease. *J Nephrol* 26:73-80
58. Cejka D, Herberth J, Branscum AJ, Fardo DW, Monier-Faugere MC, Diarra D, Haas M, Malluche HH (2011) Sclerostin and Dickkopf-1 in renal osteodystrophy. *Clin J Am Soc Nephrol* 6:877-882
59. Ferreira JC, Ferrari GO, Neves KR, Cavallari RT, Dominguez WV, dos Reis LM, Graciolli FG, Oliveira EC, Liu S, Sabbagh Y, Jorgetti V, Schiavi S, Moyses RM (2013) Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease--role of sclerostin? *PLoS One* 8:e79721
60. Marinou K, Christodoulides C, Antoniades C, Koutsilieris M (2012) Wnt signaling in cardiovascular physiology. *Trends Endocrinol Metab* 23:628-636
61. Sarzani R, Salvi F, Bordicchia M, Guerra F, Battistoni I, Pagliaricchio G, Carbonari L, Dessi-Fulgheri P, Rappelli A (2011) Carotid artery atherosclerosis in hypertensive patients with a functional LDL receptor-related protein 6 gene variant. *Nutr Metab Cardiovasc Dis* 21:150-156
62. Cozzolino M, Brandenburg V (2010) Warfarin: to use or not to use in chronic kidney disease patients? *J Nephrol* 23:648-652
63. Kruger T, Oelenberg S, Kaesler N, Schurgers LJ, van de Sandt AM, Boor P, Schlieper G, Brandenburg VM, Fekete BC, Veulemans V, Ketteler M, Vermeer C, Jähnen-Dechent W, Floege J, Westenfeld R (2013) Warfarin induces cardiovascular damage in mice. *Arterioscler Thromb Vasc Biol* 33:2618-2624

64. Beazley KE, Deasey S, Lima F, Nurminskaya MV (2012) Transglutaminase 2-mediated activation of beta-catenin signaling has a critical role in warfarin-induced vascular calcification. *Arterioscler Thromb Vasc Biol* 32:123-130
65. Zhu D, Mackenzie NC, Millan JL, Farquharson C, MacRae VE (2011) The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. *PLoS One* 6:e19595
66. Koos R, Brandenburg V, Mahnken AH, Schneider R, Dohmen G, Autschbach R, Marx N, Kramann R (2013) Sclerostin as a potential novel biomarker for aortic valve calcification: an in-vivo and ex-vivo study. *J Heart Valve Dis* 22:317-325
67. Kramann R, Brandenburg VM, Schurgers LJ, Ketteler M, Westphal S, Leisten I, Bovi M, Jahnens-Decent W, Knuechel R, Floege J, Schneider RK (2013) Novel insights into osteogenesis and matrix remodelling associated with calcific uraemic arteriolopathy. *Nephrol Dial Transplant* 28:856-868
68. Claes KJ, Viaene L, Heye S, Meijers B, D'Haese P, Evenepoel P (2013) Sclerostin: Another vascular calcification inhibitor? *J Clin Endocrinol Metab* 98:3221-3228
69. Modder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton LJ, III, Khosla S (2011) Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. *J Bone Miner Res* 26:373-379
70. Fischer DC, Mischek A, Wolf S, Rahn A, Salweski B, Kundt G, Haffner D (2012) Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase. *Ann Clin Biochem* 49:546-553
71. Kirmani S, Amin S, McCready LK, Atkinson EJ, Melton LJ, III, Muller R, Khosla S (2012) Sclerostin levels during growth in children. *Osteoporos Int* 23:1123-1130
72. Drake MT, Srinivasan B, Modder UI, Peterson JM, McCready LK, Riggs BL, Dwyer D, Stolina M, Kostenuik P, Khosla S (2010) Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. *J Clin Endocrinol Metab* 95:5056-5062